PURPOSE: The aim of this study was to investigate the outcomes correlated with our treatment strategy for prosthetic graft infection. METHODS: Seventeen patients were treated for prosthetic graft infections between 1997 and 2009. Initially, total graft excision was applied in five cases, partial graft excision was applied in six cases and graft preservation with drainage and irrigation was applied in six cases. Among the graft-preserved cases, four patients were infected with methicillin-resistant Staphylococcus aureus (MRSA) and treated with gentian violet (GV). RESULTS: The overall survival rate was 88% at 30 days and 82% at 1 year in this series. Of the excised cases, nine patients survived; however, two patients died. Among the cases in which MRSA-infected grafts were preserved, three patients survived; however, one patient died under a septicemic state. Infected graft preservation was applied at a high rate of 36%, and the mortality rate remained at 16%, without any signs of graft reinfection. CONCLUSIONS: In the treatment of infected grafts, the patient's condition should be considered in order to select the appropriate treatment in each case. Graft preservation should be considered as an alternative treatment option, especially in high-risk patients, and GV can be effective for conservative treatment of prosthetic graft infections, including MRSA infections.
PURPOSE: The aim of this study was to investigate the outcomes correlated with our treatment strategy for prosthetic graft infection. METHODS: Seventeen patients were treated for prosthetic graft infections between 1997 and 2009. Initially, total graft excision was applied in five cases, partial graft excision was applied in six cases and graft preservation with drainage and irrigation was applied in six cases. Among the graft-preserved cases, four patients were infected with methicillin-resistant Staphylococcus aureus (MRSA) and treated with gentian violet (GV). RESULTS: The overall survival rate was 88% at 30 days and 82% at 1 year in this series. Of the excised cases, nine patients survived; however, two patients died. Among the cases in which MRSA-infected grafts were preserved, three patients survived; however, one patient died under a septicemic state. Infected graft preservation was applied at a high rate of 36%, and the mortality rate remained at 16%, without any signs of graft reinfection. CONCLUSIONS: In the treatment of infected grafts, the patient's condition should be considered in order to select the appropriate treatment in each case. Graft preservation should be considered as an alternative treatment option, especially in high-risk patients, and GV can be effective for conservative treatment of prosthetic graft infections, including MRSA infections.
Authors: Paul Bahna; Tanya Dvorak; Hend Hanna; Alan W Yasko; Ray Hachem; Issam Raad Journal: Int J Antimicrob Agents Date: 2007-02-21 Impact factor: 5.283
Authors: Keith D Calligaro; Frank J Veith; John G Yuan; Nicholas J Gargiulo; Matthew J Dougherty Journal: J Vasc Surg Date: 2003-12 Impact factor: 4.268
Authors: M Batt; E Jean-Baptiste; S O'Connor; P-J Bouillanne; P Haudebourg; R Hassen-Khodja; S Declemy; R Farhad Journal: Eur J Vasc Endovasc Surg Date: 2008-04-25 Impact factor: 7.069
Authors: Ben R Saleem; Robbert Meerwaldt; Ignace F J Tielliu; Eric L G Verhoeven; Jan J A M van den Dungen; Clark J Zeebregts Journal: Am J Surg Date: 2010-01-15 Impact factor: 2.565
Authors: Sean A Kennedy; M Katharine Kennedy; Thomas F Lindsay; John Byrne; Arash Jaberi; Wayne L Gold; KongTeng Tan; Sebastian Mafeld Journal: Vasc Endovascular Surg Date: 2022-02-18 Impact factor: 1.089